Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

自2020年8月开始招募以来，方案20H0068招募了有和无近期静脉血栓栓塞病史的镰状细胞病（SCD）受试者。此外，该方案招募具有镰状细胞特征（SCT）的个人和那些认为自己是健康的非洲血统的个人。 将对两个受试者队列（SCD和SCT）进行为期两年的前瞻性随访。SCD队列中的受试者每3个月接受一次电话随访。SCT队列中的受试者每年接受一次电话随访。2年结束时，SCD队列中的所有受试者返回研究结束。与实验室医学部合作，对方案招募的所有受试者进行血栓弹性描记术。 研究血浆高凝性的试验正在开发中，收集的样品在标准条件下储存用于批分析。正在进行评估细胞衍生的细胞外囊泡和组织因子承载囊泡的测定。与校外研究人员合作，血浆中含有来自内皮下室的细胞衍生囊泡的可能性正在探索中。 截至本报告日期，所有4个研究队列中总共入组了98例研究受试者（共200例）。共有52名研究受试者完成了研究的两年随访期，并退出研究。另外8例受试者已纳入NIH CC，用于研究急性大动脉闭塞危象期间的生物标志物变异性。

Since recruitment began in August 2020, protocol 20H0068 has recruited subjects with Sickle Cell Disease (SCD) with and without a recent history of venous thromboembolism. In addition, the protocol recruits individuals with Sickle Cell Trait (SCT) and those individuals identifying themselves as healthy and of African ancestry. The two cohorts of subjects (SCD and SCT) will be followed prospectively for a period of two years. Subjects in the SCD cohort receive phone follow up every 3 months. Subjects in the SCT cohort receive annual telephone follow up. At the end of 2 years, all subjects in the SCD cohort return for study close out. In collaboration with the department of laboratory medicine, thromboelastography is performed on all subjects recruited to the protocol. Assays to study plasma hyper coagulability are under development and samples that are being collected are stored for batch analysis under standard conditions. Assays to assess cell derived extracellular vesicles and tissue factor bearing vesicles are being performed. In collaboration with extramural investigators, the possibility that plasma contains cell derived vesicles from subendothelial compartments is under exploration. As of the date of this report, a total of 98 research subjects in all four of the study cohorts out of a possible 200 have been enrolled. A total of 52 research subjects has completed the two year follow up period of the study and are off study. An additional 8 subjects have been brought into the NIH CC for study of biomarker variability during acute vast-occlusive crisis.